Search results for: 'propulsion plan processing unit'

This study carries Frost & Sullivan’s observation of bone mineral density solutions in select Asian Countries (Australia, South Korea, and China); the regulatory trends for the same have been covered, highlighting the following: • Product registration and regulatory approval process details in select Asian countries (such as the Therapeutic Goods A...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

The healthcare expenditure in Australia in the previous financial year was AUD 170.4 billion, with 10.3% of the gross domestic product (GDP), thereby allowing the country’s healthcare spending to pass the 10% mark for the first time. Healthcare expenditure continues to rise; however, the rate of increase has been curbed in the last few years. At AU...

Clinical laboratories are an essential part of the health industry. Approximately 80% of physicians' diagnoses is estimated to be the result of laboratory tests. The constant pressure to reduce healthcare spending is shifting healthcare application in favor of the laboratory, making it a more valuable part of the treatment plan. Vietnam CLT marke...

The report is expected to support the strategic decision makers in the In Vitro Diagnostic (IVD) market that are either planning to expand or enter Thailand. The forecast of the major segments can help the diagnostic companies decide their next five years business plan. Segments in the market include molecular diagnostics, immunochemistry, and mic...

Growing demand for healthcare services has created opportunities for growth and expansion in Asia-Pacific. In some countries, healthcare services companies are expanding out of their home ground, while others are strengthening and increasing their local capacity to serve the increasing demand in emerging markets. This profiling of the top 50 health...

The Malaysia healthcare outlook addresses the investment opportunities across various segments. The study explores the developments in the hospital industry, IVD and POCT industry, pharmaceutical industry, biotechnology industry, medical devices industry, connected health industry, and the aged care industry in the country. The study explores oppor...

This research service presents an overview of hospital-acquired infections, global scenario, key incidences and trends in Malaysia. The study is segmented based on the type of infections  blood stream, respiratory tract, urinary tract, surgical site and clinical sepsis. It provides in-depth geographical analysis of HAI incidence and trends in thes...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...